Skip to Main Content

Paper Details

Concurrent RB1 and TP53 Alterations Define a Subset of EGFR-Mutant Lung Cancers at risk for Histologic Transformation and Inferior Clinical Outcomes.
J Thorac Oncol
206
2019
EGFR, EGFR-Mutant Lung Cancers, EGFR-mutant, EGFR-mutant lung cancers, EGFR/, NSCLC, Patients, RB transcriptional corepressor 1, RB1, SCLC, TP53, TP53-mutant lung cancers, Triple-mutant lung cancers, apolipoprotein B, cytidine, cytidine deaminase, lung cancers, patients, triple, triple-mutant cancers, triple-mutant lung cancers, tumor protein p53, tyrosine, tyrosine kinase
Author NameAffiliation
Hira RizviDruckenmiller Center for Lung Cancer Research, Memorial Sloan Kettering Cancer Center
Ronglai ShenMemorial Sloan Kettering Cancer Center
Gregory J RielyMemorial Sloan Kettering Cancer Center, New York Weill Cornell Medical College
Marc LadanyiDruckenmiller Center for Lung Cancer Research, Memorial Sloan Kettering Cancer Center
Dana Pe'erSloan Kettering Institute, Memorial Sloan Kettering Cancer Center
Charles M RudinMemorial Sloan Kettering Cancer Center, New York Druckenmiller Center for Lung Cancer Research, New York Weill Cornell Medical College
  • 1 - 6

Datasets

Release 1.2